Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting.

Michael Seiberl (First author), Julia Feige (Co-author), Patrick Hilpold, Wolfgang Hitzl (Co-author), Lukas Machegger (Co-author), Arabella Buchmann, Michael Khalil, Eugen Trinka (Co-author), Andrea Harrer (Co-author), Peter Wipfler (Co-author), Tobias Moser* (Last author)

*Corresponding author for this work

Research output: Contribution to journalOriginal Article (Journal)peer-review

7 Citations (Web of Science)
Original languageEnglish
JournalINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume24
Issue number4
DOIs
Publication statusPublished - 17 Feb 2023

Keywords

  • DISEASE-ACTIVITY
  • ORAL CLADRIBINE
  • TIME
  • Multiple Sclerosis
  • Recurrence
  • Prospective Studies
  • Intermediate Filaments
  • Humans
  • Cladribine
  • Biomarkers
  • Neurofilament Proteins

Cite this